RecoveryRx® is FDA 510(k) cleared (K190251) for adjunctive treatment of postoperative pain. Reduction of postoperative edema is a published study finding within that clearance, not a cleared indication. Electrome's Post Surgical Recovery program connects this cleared device with clinician-directed recovery workflows designed for outpatient, ambulatory, and home based recovery environments.
RecoveryRx is FDA-cleared for clinical use in postoperative settings. The device is listed under 510(k) K190251 as a shortwave diathermy device for use other than applying therapeutic deep heat, and the FDA summary describes it as a pulsed shortwave therapy device utilizing low voltage electronics. Electrome distributes this separate prescription-only device to clinicians and provider networks.
Modern surgery is increasingly defined by outpatient procedures, shorter hospital stays, faster mobilization, enhanced recovery pathways, opioid sparing protocols, and decentralized rehabilitation.
Healthcare systems are under growing pressure to improve recovery efficiency, patient outcomes, opioid stewardship, patient adherence, home recovery support, and cost management.
Enhanced Recovery After Surgery (ERAS) programs have accelerated this transition by emphasizing multimodal recovery approaches that reduce perioperative opioid exposure while supporting earlier recovery and mobilization. Reviews of ERAS pathways consistently highlight non-opioid and multimodal pain management strategies as core components of modern perioperative care.
Electrome believes wearable bioelectric therapy may become an increasingly relevant component within this broader recovery ecosystem.
The Recovery Burden
Postoperative recovery involves far more than pain alone. Patients frequently experience inflammation, edema, mobility limitation, sleep disruption, fatigue, medication burden, delayed rehabilitation, and reduced activity tolerance.
These challenges can affect patient satisfaction, rehabilitation participation, complication risk, recovery timelines, and healthcare utilization.
At the same time, providers are searching for recovery tools that are low burden, scalable, wearable, non-pharmacologic, suitable for home use, and compatible with modern recovery pathways. This shift has created growing interest in wearable recovery technologies capable of supporting patients beyond the hospital setting.
What Is Pulsed Shortwave Therapy?
Pulsed Shortwave Therapy (PSWT) uses pulsed electromagnetic fields rather than direct conductive electrical stimulation. Unlike TENS systems, PSWT devices do not require electrical current to pass through the skin via conductive electrodes.
Wearable pulsed shortwave systems are designed around low power electromagnetic signaling, wearable form factors, prolonged use models, and ambulatory recovery support.
FDA-cleared PSWT systems such as RecoveryRx® and ActiPatch® operate at a carrier frequency of 27.12 MHz, an internationally allocated Industrial, Scientific, and Medical (ISM) frequency commonly used in regulated medical technologies. Because wearable PSWT systems are generally subsensory, they may support long duration recovery workflows without requiring perceptible stimulation during therapy.
Published Clinical Literature
Published literature involving pulsed shortwave and related electromagnetic therapies has explored postoperative pain, edema, rehabilitation, musculoskeletal recovery, and ambulatory recovery workflows.
A randomized study involving cesarean section recovery reported that pulsed electromagnetic field therapy following surgery was associated with reductions in postsurgical pain, analgesic use, wound exudate, and edema within the studied population.
A 2023 orthopedic case series evaluating wearable pulsed shortwave therapy following ambulatory orthopedic procedures reported feasibility and potential analgesic benefit while emphasizing the need for larger controlled studies.
More recent sham controlled pilot studies evaluating pulsed shortwave therapy in postoperative pain settings reported that PSWT did not reduce pain scores or opioid consumption to statistically significant or clinically meaningful levels within the studied populations.
This variability is important. Clinical outcomes may depend on procedure type, timing of therapy, device architecture, waveform parameters, treatment duration, patient population, rehabilitation protocol, and background analgesic regimen. Electrome therefore maintains an evidence aware and indication specific approach to clinical positioning.
FDA 510(k) ClearedPostoperative PainEdema ReductionClinician-Directed
RecoveryRx® is an FDA 510(k) cleared PSWT device for clinician-directed care, used as an adjunctive therapy for postoperative pain and the reduction of postoperative edema in superficial soft tissue. Available through the Electrome provider program.
Traditional postoperative care is episodic. Recovery, however, occurs continuously at home, during sleep, during rehabilitation, while walking, and while returning to daily activity.
Electrome believes wearable therapeutic systems are compelling because they may integrate naturally into these longer duration recovery environments. Potential advantages of wearable recovery systems may include low treatment burden, improved convenience, ambulatory use, continuous workflow integration, and reduced dependence on in-clinic therapy sessions.
The company's broader platform strategy combines wearable therapeutics, provider directed recovery workflows, AI assisted engagement, outcomes tracking, and decentralized recovery infrastructure.
"Recovery is no longer confined to hospitals. The future of postoperative care will increasingly involve wearable systems, intelligent software, and recovery infrastructure that follows the patient home."
Orthopedics, Rehabilitation & Ambulatory Surgery
Electrome believes the largest opportunity for wearable recovery infrastructure may exist within orthopedic surgery, musculoskeletal recovery, ambulatory surgery centers, rehabilitation programs, and outpatient recovery pathways.
Healthcare systems increasingly prioritize earlier discharge, improved recovery adherence, opioid reduction, reduced readmission risk, and scalable home recovery. Wearable bioelectric therapy aligns naturally with these trends because the systems are non-invasive, portable, wearable, low burden, and compatible with home recovery.
"Postoperative recovery is becoming increasingly decentralized. Wearable bioelectric systems may eventually become an important component within broader multimodal recovery ecosystems."
Commercial Deployment Strategy
Electrome's current recovery infrastructure includes RecoveryRx® clinical systems, provider workflows, wholesale provider distribution, postoperative recovery programs, future digital engagement infrastructure, and retail to clinical recovery pathways.
Future platform initiatives may include provider dashboards, recovery adherence workflows, outcomes tracking, AI assisted recovery optimization, and integrated patient engagement systems. However, future platform capabilities remain forward-looking and subject to operational, scientific, and regulatory development.
Current Program Status
Post Surgical Recovery is a commercial program anchored by RecoveryRx®, which is FDA 510(k) cleared (K190251) for adjunctive treatment of postoperative pain. Reduction of postoperative edema is a published study finding within that clearance, not a cleared indication. This clearance supports clinician-directed use across orthopedic, ambulatory surgical, and postoperative recovery workflows.
Electrome does not claim universal postoperative efficacy, replacement of standard surgical care, prevention of surgical complications, or superiority to all other recovery modalities. Clinical positioning remains evidence aware, indication specific, workflow oriented, and regulatory disciplined.
Broader digital platform capabilities, expanded recovery workflows, and future indication extensions remain forward-looking and subject to additional clinical and regulatory development.
This page is provided for scientific and informational purposes only. The Post Surgical Recovery program is connected to FDA-cleared pulsed shortwave therapy infrastructure. Statements regarding future workflows, recovery systems, digital infrastructure, and expanded applications are forward-looking and subject to scientific, clinical, operational, and regulatory uncertainty. No statement on this page should be interpreted as medical advice or as a claim regarding diagnosis, treatment, cure, mitigation, or prevention of disease beyond cleared indications and supported evidence.
